Essential elements of genetic cancer risk assessment, counseling, and testing: Updated recommendations of the National Society of genetic Counselors

Journal of Genetic Counseling

Volumn 21, Issue 2, 2012, Pages 151-161

  Riley, Bronson D ^a   Culver, Julie O ^b   Skrzynia, Cécile ^c   Senter, Leigha A ^d   Peters, June A ^e   Costalas, Josephine W ^f   Callif Daley, Faith ^g   Grumet, Sherry C ^h   Hunt, Katherine S ⁱ   Nagy, Rebecca S ^j   McKinnon, Wendy C ^k   Petrucelli, Nancie M ^l   Bennett, Robin L ^m   Trepanier, Angela M ⁿ  

^a Southeast Nebraska Cancer Center   (United States)

^b Division of Clinical Cancer Genetics   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f St Mary Regional Cancer Center   (United States)

^g CHILDREN S MEDICAL CENTER   (United States)

^h MONMOUTH MEDICAL CENTER   (United States)

ⁱ Mayo Clinic   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k Vermont Regional Genetics Center   (United States)

^l KARMANOS CANCER INSTITUTE   (United States)

^m UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

ⁿ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Cancer genetic counseling; Family history; Genetic testing; Hereditary cancer; Informed consent; Psychosocial assessment; Risk assessment

Indexed keywords

ARTICLE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; MANPOWER; NEOPLASM; RISK ASSESSMENT;

GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 84863615237     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-011-9462-x     Document Type: Article

References (79)

1. Amir, E., Freedman, O. C., Seruga, B., & Evans, D. G. (2010). Assessing women at high risk of breast cancer: a review of risk assessment models. Journal of the National Cancer Institute, 102(10), 680-691.
2. American College of Medical Genetics (ACMG). (1995). Genetic Testing in Children and Adolescents, Points to Consider: Ethical, Legal and Psychosocial Implications. American Journal of Human Genetics, 57, 1233-1241.
3. American Society of Clinical Oncology (ASCO). (2003). ASCO policy statement update: genetic testing for cancer susceptibility. Journal of Clinical Oncology, 21(12), 2397-2406.
4. American Society of Human Genetics (ASHG) Social Issues Subcommittee on Familial Disclosure. (1998). ASHG statement. Professional disclosure of familial genetic information. American Journal of Human Genetics, 62(2), 474-483.
5. Antoniou, A. C., Pharoah, P. P., Smith, P., et al. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer, 91(8), 1580-90. (Pubitemid 39486366)
6. Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., et al. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet, 376(9737), 245-251.
7. Baum, A., Friedman, A. L., & Zakowski, S. G. (1997). Stress and genetic testing for disease risk. Health Psychology, 16(1), 8-19. (Pubitemid 127465950)
8. Bennett, R. L. (1999). The practical guide to the genetic family history. New York: Wiley.
9. Bennett, R. L. (2010). The practical guide to the genetic family history (2nd ed.). Hoboken: Wiley-Blackwell.
10. Bennett, R. L., French, K. S., Resta, R. G., & Doyle, D. L. (2008). Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 17(5), 424-433.
11. Braithwaite, D., Emery, J., Walter, F., Prevost, A. T., & Sutton, S. (2006). Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. Familial Cancer, 5(1), 61-75. (Pubitemid 43384321)
12. Brown, K. L., Moglia, D. M., & Grumet, S. (2006). Genetic counseling for breast cancer risk: general concepts, challenging themes and future directions. Breast Disease, 27, 69-96.
13. Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., et al. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. Journal of Clinical Oncology, 28(3), 375-379.
14. Chivers-Seymour, K., Addington-Hall, J., Lucassen, A., & Foster, C. (2010). What facilitates or impedes family communication following genetic testing for cancer risk? A systematic review and meta-synthesis of primary qualitative research. Journal of Genetic Counseling, 19(4), 330-342.
15. Claus, E. B., Risch, N., & Thompson, W. D. (1993). The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Research and Treatment, 28(2), 115-20. (Pubitemid 24056083)
16. Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., (1997). BRCA1 mutations in women attending clinics that evaluate breast cancer risk. The New England Journal of Medicine 336, 1409-1415. (Pubitemid 27208599)
17. Croyle, R. T., Smith, K. R., Botkin, J. R., Baty, B., & Nash, J. (1997). Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychology, 16(1), 63-72. (Pubitemid 127465954)
18. Culver, J. O., Lowstuter, K., & Bowling, L. (2006). Assessing breast cancer risk and BRCA1/2 carrier probability. Breast Disease, 27, 5-20.
19. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Journal of the American Medical Association, 304(9), 967-975.
20. Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L., Kalkbrenner, K. J., et al. (2000). Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: findings from p53 and BRCA1 testing programs. Journal of Clinical Oncology, 18(10), 2135-2142. (Pubitemid 30324367)
21. Edwards, A., Gray, J., Clarke, A., Dundon, J., Elwyn, G., Gaff, C., et al. (2008). Interventions to improve risk communication in clinical genetics: systematic review. Patient Education and Counseling, 71(1), 4-25.
22. Eng, C., Hampel, H., & de la Chapelle, A. (2001). Genetic testing for cancer predisposition. Annual Review of Medicine, 52, 371-400. (Pubitemid 32195331)
23. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. (2009). Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35-41.
24. Evans, D. G. R., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006). Malignant transformation and new primary tumors after therapeutic radiation for benign disease: substantial risks in certain tumor prone syndromes. Journal of Medical Genetics, 43, 289-294.
25. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. Journal of the National Cancer Institute, 90(18), 1371-1388. (Pubitemid 28439961)
26. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361(2), 123-134.
27. Forrest, L. E., Burke, J., Bacic, S., et al. (2008). Increased genetic counseling support improves communication of genetic information in families. Genetics in Medicine, 10(3), 167-72. (Pubitemid 351416812)
28. Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood M. E., Mullineau L., et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology 16, 2417-2425. (Pubitemid 28309036)
29. Gail, M. H., Brinton, L. A., Byar, D. P., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81(24), 1879-86. (Pubitemid 20026073)
30. Gallo, A. M., Angst, D. B., & Knafl, K. A. (2009). Disclosure of genetic information within families. The American Journal of Nursing, 109(4), 65-69.
31. Gaff, L., & Bylund, C. (Eds.). (2010). Family communication about genetics. New York: Oxford University Press.
32. Geller, G., Botkin, J. R., Green, M. J., Press, N., Biesecker, B. B., Wilfond, B., et al. (1997). Genetic testing for susceptibility to adultonset cancer. The process and content of informed consent. Journal of the American Medical Association, 277(18), 1467-1474. (Pubitemid 27208890)
33. Hampel, H., Sweet, K., Westman, J. A., Offit, K., & Eng, C. (2004). Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. Journal of Medical Genetics, 41(2), 81-91. (Pubitemid 38221744)
34. * on direct-to-consumer genetic testing in the United States. Journal of Obstetrics and Gynecology, 110(6), 1392-1395. (Pubitemid 351326086)
35. Jenkins, J., Calzone, K. A., Dimond, E., Liewehr, D. J., Steinberg, S. M., Jourkiv, O., et al. (2007). Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling. Genetics in Medicine, 9(8), 487-95. (Pubitemid 47282036)
36. Kenen, R. H., Shapiro, P. J., Friedman, S., & Coyne, J. C. (2007). Peer-support in coping with medical uncertainty: discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psycho-Oncology, 16(8), 763-771. (Pubitemid 47249178)
37. Kloos, R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., et al. (2009). Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19(6), 565-612.
38. Koehly, L. M., Peters, J. A., Kenen, R., Hoskins, L. M., Ersig, A. L., Kuhn, N. R., et al. (2009). Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions. American Journal of Public Health, 99(12), 2203-2209.
39. Konstantopoulou, I., Pertesi, M., Fostira, F., Grivas, A., & Yannoukakos, D. (2009). Hereditary cancer predisposition syndromes and preimplantation genetic diagnosis: where are we now? Journal of Balkan Union Oncology, 14(Suppl 1), S187-192.
40. Lerman, C., Biesecker, B., Benkendorf, J. L., Kerner, J., Gomez-Caminero, A., Hughes, C, & Reed, M. M. (1997). Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. Journal of the National Cancer Institute, 89(2), 148-157. (Pubitemid 27034791)
41. Ligtenberg, M. J., Kuiper, R. P., Chan, T. L., Goossens, M., Hebeda, K. M., Voorendt, M., et al. (2009). Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nature Genetics, 41(1), 112-117.
42. Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., et al. (2006). Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. Journal of the American Medical Association, 296(12), 1507-17. (Pubitemid 44465515)
43. Lindor, N. M., McMaster, M. L., Lindor, C. J., & Greene, M. H. (2008). Concise handbook of familial cancer susceptibility syndromes-second edition. Journal of the National Cancer Institute. Monographs, 38, 1-93.
44. Lindor, N. M., Johnson, K. J., Harvey, H., Pankratz, V. S., Domchek, S. M., Hunt, K., Wilson, M., Smith, C. S., & Couch, F. (2010). Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Familial Cancer, 9, 405-402.
45. McKinnon, W., Naud, S., Ashikaga, T., Colletti, R., & Wood, M. (2007). Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing. Journal of Genetic Counseling, 16(4), 433-456. (Pubitemid 47305500)
46. Meiser, B. (2005). Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psycho-Oncology, 14(12), 1060-1074. (Pubitemid 43019695)
47. Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328-35. (Pubitemid 41115389)
48. ® Cancer Genetics Risk Assessment and Counseling. Retrieved from http://cancer. gov/cancertopics/pdq/genetics/risk-assessment-andcounseling/HealthProfessional.
49. National Comprehensive Cancer Network (NCCN) 2 (2011) NCCN Clinical Practice Guidelines in Oncology, Colorectal Cancer Screening. Retrieved from http://www.nccn.org/professionals/physician-gls/pdf/colorectal-screening.pdf
50. National Society of Genetic Counselors. (2007). NSGC Position Statement: Direct to Consumer Genetic Testing. Retrieved from http://www.nsgc.org/Advocacy/ PositionStatements/tabid/107/Default.aspx.
51. Nelson, R. M., Botkjin, J. R., Kodish, E. D., Levetown, M., Truman, J. T., Wilfond, B. S., et al. (2001). Ethical issues with genetic testing in pediatrics. Pediatrics, 107(6), 1451-1455. (Pubitemid 32525235)
52. Offit, K., Kohut, K., Clagett, B., Wadsworth, E. A., Lafaro, K. J., Cummings, S., et al. (2006). Cancer genetic testing and assisted reproduction. Journal of Clinical Oncology, 24(29), 4775-4782. (Pubitemid 46630942)
53. Offit, K., Groeger, E., Turner, S., Wadworth, E. A., & Weiser, M. A. (2004). The "duty to warn" a patient's family members about hereditary disease risks. Journal of the American Medical Association, 292(12), 1469-73. (Pubitemid 39258340)
54. Parmigiani, G., Berry, D., & Aguilar, O. (1998). Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American Journal of Human Genetics, 62(1), 145-58. (Pubitemid 28093844)
55. Patenaude, A. F., & Juliean-Reynier, C. (2008). Cancer genetic testing: current and emerging issues. Psycho-Oncology, 17(8), 733-736.
56. Pieterse, A. H., Ausems, M. G., Van Dulmen, A. M., Beemer, F. A., & Bensing, J. M. (2005). Initial cancer genetic counseling consultation: change in counselees' cognitions and anxiety, and association with addressing their needs and preferences. American Genetics in Medicine, 137(1), 27-35. (Pubitemid 41105531)
57. Pieterse, A. H., van Dulmen, A. M., Beemer, F. A., Bensing, J. M., & Ausems, M. G (2007). Cancer genetic counseling: communication and counselees' post-visit satisfaction, cognitions, anxiety, and needs fulfillment. Journal of Genetic Counseling, 16(1), 85-96. (Pubitemid 46355049)
58. Pilarski, R. (2009). Cowden syndrome: a critical review of the clinical literature. Journal of Genetic Counseling, 18(1), 13-27.
59. Quillin, J. M., Bodurtha, J. N., Siminoff, L. A., & Smith, T. J. (2010). Exploring hereditary cancer among dying cancer patients-a crosssectional study of hereditary risk and perceived awareness of DNA testing and banking. Journal of Genetic Counseling, 19(5), 497-525.
60. Qureshi N., Wilson, B., Santaguida P., Carroll J., Allanson J., Ruiz Culebro C., et al. (2007). Collection and Use of Cancer Family History in Primary Care. Evidence Report/Technology Assessment No. 159 (prepared by the McMaster University Evidencebased Practice Center, under Contract No. 290-02-0020). Rockville, MD: Agency for Healthcare Research and Quality, AHRQ Publication No. 08-E001.
61. Rich, E. C., Burke, W., Heaton, C. J., Haga, S., Pinsky, L., Short, M. P., et al. (2004). Reconsidering the family history in primary care. Journal of General Internal Medicine, 19(3), 273-280. (Pubitemid 38388939)
62. Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 28(5), 893-901.
63. Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., et al. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology, 28(20), 3219-3226.
64. Saslow, D., Boetes, C., Burke, W., Harms, S., Leach, M. O., Lehman, C. D., American Cancer Society Breast Cancer Advisory Group, et al. (2007). American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. A Cancer Journal for Clinicians, 57(2), 75-89. (Pubitemid 46535708)
65. Schneider, K. A. (2002). Counseling about cancer: Strategies for genetic counseling (2nd ed.). New York: Wiley-Liss.
66. Schneider, K. A., DiGianni, L. M., Patenaude, A. F., Klar, N., Stopfer, J. E., Calzone, K. A., et al. (2004). Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genetic Testing and Molecular Biomarkers, 8(3), 222-8. (Pubitemid 39586789)
67. Schneider, K. A., Chittenden, A. B., Branda, K. J., Keenan, M. A., Joffe, S., Patenaude, A. F., et al. (2006). Ethical issues in cancer genetics: whose information is it? Journal of Genetic Counseling, 15(6), 491-503. (Pubitemid 44900665)
68. Sivell, S., Iredale, R., Gray, J., & Coles, B. (2007). Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database of Systematic Reviews (2), CD003721.
69. Spits, C., De Rycke, M., Van Ranst, N., Verpoest, W., Lissens, W., Van Steirteghem, A., et al. (2007). Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenatal Diagnosis, 27(5), 447-56. (Pubitemid 47164344)
70. Stultiens, B. P., Nys, H., Cassiman, J. J., & Dierickx, K. (2006). Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clinical Genetics, 70, 374-381. (Pubitemid 44515636)
71. Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. (2004). Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. Journal of Genetic Counseling, 13(2), 83-114. (Pubitemid 39024176)
72. Trepanier, A., Allain, D., & Cohen S. (2011). Assessing the use of various service delivery models in cancer genetics. Abstracr 366. American College of Medical Genetics.
73. Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., et al. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet, 376(9737), 235-244.
74. Tyrer, J., Duffy, S. W., & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 23(7), 1111-30. (Pubitemid 38477070)
75. United States Preventive Services Task Force (USPSTF). (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annals of Internal Medicine, 143(5), 355-61.
76. Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261-8. (Pubitemid 38256271)
77. Weissman, S. M., Bellcross, C., Bittner, C. C., Freivogel, M. E., Haidle, J. L., Kaurah, P., et al. (2011). Genetic counseling considerations in the evaluation of families for Lynch syndromea review. Journal of Genetic Counseling, 20(1), 5-19.
78. Weitzel, J. N., Lagos, V. I., Cullinane, C. A., Gambol, P. J., Culver, J. O., Blazer, K. R., et al. (2007). Limited family structure and BRCA gene mutation status in single cases of breast cancer. Journal of the American Medical Association, 297(23), 2587-2595. (Pubitemid 46961030)
79. Wham, D., Vu, T., Chan-Smutko, G., Kobelka, C., Urbauer, D., & Heald, B. (2010). Assessment of clinical practices among cancer genetic counselors. Familial Cancer, 9(3), 459-468.